Gilead Sciences (GILD) Tops Q3 EPS by 38c, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. NVDA
5. STZ
6. MSFT
7. SPY
8. SKYD
9. IBM
10. CRWV

Go back to Gilead Sciences (GILD) Tops Q3 EPS by 38c, Offers Guidance

Gilead Sciences Announces Third Quarter 2023 Financial Results

November 7, 2023 4:02 PM EST

Product Sales Excluding Veklury Increased 5% Year-Over-Year to $6.4 billion

Biktarvy Sales Increased 12% Year-Over-Year to $3.1 billion

Oncology Sales Increased 33% Year-Over-Year to $769 million

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.

Gilead has now delivered two years of consistent growth in our base business. In the third quarter, this continued growth was driven by both Virology and Oncology, said Daniel ODay, Gilead's Chairman and Chief Executive Officer. Our clinical... More